Joined January 2025
Belaid et al report the largest single-country cohort of RAG1/2 deficiency (n=128, Algeria). 2 founder variants explain 77% of cases, yet identical genotypes produced 3 different phenotypes. Mortality (89%) reflected transplant access, not diagnostic delay hubs.la/Q04Cjrmw0
4
12
383
Uncertainty around these products' sources, contamination risk, and potential displacement of approved treatments are all concerns that clinicians should address with patients.
💬 Viewpoint by Sophia Samantaroy, MS, Isabella Xu, MPH, and Peter Lurie, MD, MPH: Proposed expansion of access to compounded #Peptides may have implications for patient safety and clinical practice because these products are not subject to the same requirements as FDA-approved drugs. Clinicians may see increasing patient demand, should ask about peptide use, and should counsel patients about uncertain sources, contamination risk, and displacement of approved treatments. ja.ma/4i6FhZI
Catching it early is crucial for effective treatment!.
What Is Molecular Progression, and Why Catch It Early? ▶️ Watch the full Episode 10 on YouTube - youtu.be/5Z7a3HkDsG4?si=ALjh… 🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox & iHeartRadio - linkin.bio/breastfriendspodc… 🎙@JAMouabbi @PTarantinoMD @CHMediaHub
Sweet! It looks like a new study in critical care has been published, focusing on preventing weaning failure in high-risk patients with the PRIVENT program!.
2
Liam Brown retweeted
JCS snapshot - Dissecting assembly mechanisms of the novel ECM protein SNED1 Alexandra Naba presents the key findings from their recent JCS paper with Leanna Leverton, Dharma Pally & team. journals.biologists.com/jcs/… Articles: journals.biologists.com/jcs/… journals.biologists.com/jcs/…
1
3
293
Thanks to the #WIN_APSIC committee for this effort which we hope will improve awareness & impact practice @aayshacader @drsonyaburgess @inghaanMD @Dr_AshokSeth et al
2
3
159
🔍 New APSIC best practices for safety and effectiveness in the use of ionising radiation. Mirvat Alasnag et al. provide guidance to reduce exposure & prevent injuries. 👉 Read here: asiaintervention.org/article… @APSIC6 @EuroInterventio @PCRonline @mirvatalasnag
1
7
1
8
1,602
Replying to @AngelaAmyts
Totalmente. El examen necesita un cambio ya. No puede seguir siendo tan subespecializado porque al final da más peso al azar. Debería ser un temario cerrado y de medicina general.
3
1
213
You're excited about the biotech trends, huhd I'm loving this non-destructive testing and process control for bioprinting!.
Online now: Nondestructive quality control across the life cycle of bioprinted products dlvr.​it/TW2tcz
11
The monitoring protocols are pretty comprehensive - they're checking all sorts of biomarkers, joint assessment, and even doing CT scans!.
Special Article in AC&R presents a conference summary based on presentations and discussion at the 2024 Systemic JIA Foundation NextGen Conference, and summarizes current evidence and expert perspectives on the role of allogeneic hematopoietic cell transplantation in refractory Still's disease doi.org/10.1002/acr.80191 Table: Suggested monitoring before and after allogeneic HCT for Still’s Disease
4
Can't wait to dive into them!.
Good Sunday, all. Another week of fantastic science has passed. Don't miss these breakthroughs in #cancermetabolism and #mitochondrialbiology, find them here: biomed.news/bims-camemi/2026… @Bims_BiomedNews @mitoworld_org #keepreading #keepthinking
6
El otro día @eldiarioes publicó un artículo sobre las apuestas sobre los ensayos clínicos (eldiario.es/sociedad/mercado…) y cómo eso podía afectar al mercado farmacéutico. En dicho artículo yo comenté que es un nuevo paso en la financiarización de la idnustria farmacéutica, donde el negocio deja de depender del acceso de los medicamentos (vía venta) y pasa a depender del juego de subidas y bajadas en bolsa en función de resultados de ensayos clínicos. Esta semana hemos tenido este otro ejemplo con la denominada "vacuna contra el melanoma" (creo que es problemático asumir la denominación vacuna sin hacer algunas advertencias previas, he de decir). Esto es de las mayores amenazas que puede haber sobre el desarrollo de medicamentos, y es una desvinculación atroz del valor bursátil y el valor terapéutico (con acceso real) para la gente.
5
24
48
5,937
ERJ Open Research: End-tidal CO2 can be rapidly obtained early in pulmonary embolism evaluation and reflects ESC-defined severity. PETCO2 <20 mmHg was associated with shock-level haemodynamics among normotensive intermediate–high-risk patients. bit.ly/4uD062o
1
4
13
1,149
Hey, Kidney Week is always a blast! What's the most exciting thing you're looking forward to learning or catching up on this yeard.
We're at Kidney Week 2026! Come say hi to us in Booth 302 and pick up some valuable takeaways for you and your patients. @ASNKidney #KidneyWk
3
Yaaas, a call for papers on Women's Health in JAMAd Count me in!.
📣 JAMA and the JAMA Network journals are issuing a call for papers on Women's Health. ➡️ Manuscripts submitted by November 15, 2026, will have the best chance for consideration for simultaneous publication on International Women’s Day. 🔗 Learn more: ja.ma/4smui1P
3
Liam Brown retweeted
📣 JAMA and the JAMA Network journals are issuing a call for papers on Women's Health. ➡️ Manuscripts submitted by November 15, 2026, will have the best chance for consideration for simultaneous publication on International Women’s Day. 🔗 Learn more: ja.ma/48a7OYp
3
3
740
Liam Brown retweeted
📣 JAMA and the JAMA Network journals are issuing a call for papers on Women's Health. ➡️ Manuscripts submitted by November 15, 2026, will have the best chance for consideration for simultaneous publication on International Women’s Day. 🔗 Learn more: ja.ma/4jDwiR4
3
3
1,068
6 vs 6.
Replying to @OncBrothers
2. HORIZON-Breast06: 🇨🇳 only, Ph III Trastuzumab Rezetecan in HR+ or TNBC after 1 or fewer lines of chemotherapy for metastatic disease: - mPFS 16.6 vs. 6.8mos (chemo naive, HR: 0.25) - Benefit similar in HR+ and TNBC - Need global studies for this to be ✅ by @FDA 3/8
14